Pharma Focus Asia

Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA

Tuesday, May 30, 2017

Lysogene, a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced the completion of enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).

SAMOS is particularly important as there is currently no validated biomarker in MPS IIIA that reflects CNS disease progression and response to future therapy. SAMOS has therefore been designed to evaluate clinical change in untreated MPS IIIA patients. As agreed with the regulatory authorities, this international multi-center study is to function as a non-concurrent control group for the upcoming Lysogene Phase II/III pivotal gene therapy trial, scheduled to start during the first quarter of 2018.

“Lysogene has taken a very proactive and rigorous approach to gaining a better understanding of MPS IIIA,” said Dr. Benedicte Heron, neuro-pediatrician (Armand-Trousseau Hospital, APHP Paris, France). “The company’s efforts in running this observational study will support its own plans for future research and therapy development while also aiding the scientific community as a whole.”

“Enrollment of the 23 children from 5 countries has been rapid, reflecting the strong interest from the key opinion leaders running our clinical sites and the network of patient associations to address the significant unmet needs in MPS IIIA,” stated Samantha Parker, Chief Patient Access Officer at Lysogene.

In designing SAMOS, Lysogene established the first international neurologist and neuropsychologist MPS IIIA expert group. This group determined that the most scientifically rigorous and relevant primary endpoint was cognitive assessment using the Bayley Scales of Infant and Toddler Development, 3rd edition (BSID-III). The Vineland Adaptive Behavior Scale, 2nd edition (VABS-II) was determined to be the most appropriate as a secondary endpoint measure.

Further validating the choice of endpoints for neuronopathic MPS, a consensus meeting, among international experts, was organised in London, 2-3 December 2016, by an academic group in consultation with the UK Society for Mucopolysaccharide Diseases and US National MPS Society, and chaired by Elsa Shapiro1. From all the available instruments the BSID-III is recommended to measure cognitive outcomes and the recommended instrument to measure adaptive behavior is the VABS-II, using the extended interview format (van der Lee, 2017).2

Lysogene previously issued baseline data from SAMOS assessing cognitive age using the BSID-III in the first 15 patients, aged between 3 and 8 years old, which confirmed the progressive intellectual decline, hyperactivity and behavior changes in these individuals.

Lysogene has also successfully completed a Phase I/II trial and 5-year follow-up study of four MPS IIIA patients with no adverse events related to the treatment.

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024